Wound packing material comprising chemoeffector
A wound packing material, particularly suitable for use in negative pressure wound therapy, comprising a porous material admixed with a chemoattractant. This disclosure further provides methods of manufacturing the wound packing material, and therapeutic methods of using the wound packing material.
1. A wound packing material comprising an open-cell polymer selected from a polyvinyl alcohol (PVA) or polyurethane (PU) admixed with at least one chemoattractant agent that is chemoattractant to a microorganism, wherein the at least one chemoattractant agent is selected from the group consisting of N-(3-hydroxydodecanoyl)-L-homoserine lactone, N-Dodecanoyl-L-homoserine lactone, N-Tetradecanoyl-L-homoserine lactone, N-(3-Oxotridecanoyl)-L-homoserine lactone, N-Hexanoyldecanoyl-L-homoserine lactone, enzymatic hydrolysate of casein (Trypticase), N-acetylneuraminic acid from egg mucin, L-aspartate, human intestinal mucus proteins, canine intestinal mucus proteins, porcine intestinal mucus proteins, quorum sensing autoinducer 2 (AI-2), α-Methyl-DL-aspartate (AMA), (±)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-L-aspartate (NMA), (2-Imino-4-oxo-thiazolidin-5-yl)-acetic acid (IOTA), cis-1,2-cyclohexane-dicarboxylic acid (CHDCA), phthalic acid (PA), cis-(2R, 3S)-2,3-piperidine dicarboxylic acid (cis-PDA), L-malic acid (LMA), D-glucose, D-galactose, 3,4-dihydroxymandelic acid, D-ribose, L-arabinose, L-sorbose, tryptose, gamma-aminobutyrate (GABA), L-fucose, D-galactose, ferret airway mucus, human respiratory tract glycolipids, human salivary mucins, human nasal mucin, Mucin Type O-glycans, secretory gel-forming mucins, MUC2, MUC5AC, MUC5B, MUC6, MUC7, MUC1, MUC3, MUC4, MUC12, MUC13, MUC17U, Human Milk Oligosaccharides, bovine submaxillary mucin, bacterial chemotaxin, CCL1, TCA3, 1-309, MCAF, JE, LD78α, CCL3L1, LD78β, CCL3P1, CCL3L2, CCL3L3, LD78β, CCL4, CCL4L1, LAG-1, CCL4L2, LAG-1, MARC, CCL8, CCL11, CCL13, CCL14, HCC-1, CCL15, HCC-2, CCL16, HCC-4, LEC, CCL17, TARC, ABCD-2, CCL18, DC-CK-1, PARC, AMAC-1, Exodus-3, LARC, Exodus-1, 6Ckine, SLC, Exodus-2, MDC, STCP-1, AMCD-1, CCL23, CKβ8, MPIF-1, CCL24, MPIF-2, TECK, CCL26, IMAC, CCL27, CTACK, ILC, ESKINE, CCL28, MEC, CXCL1, GRO-α, MGSA-α, p-CXCL1, CXCL1P, CXCL2, GRO-β, MGSA-β, CXCL3, GRO-γ, MGSA-γ, CXCL4, PF4, CXCL4L1, PF4V1, PF4-ALT, CXCL4V1, CXCL5, ENA-78, CXCL6, GCP-2, PPBP, NAP-2, beta-TG, CTAP-III, p-CXCL7, PPBPL1, CXC:10, IP10, CRG-2, CXCL11, I-TAC, SDF-1α, SDF-1β, SDF-1γ, BCA-1, BLC, CXCL14, CXCL16, SR-PSOX, CXCL17, XCL1, Lymphotactin, SCM-1α, ATAC, XCL2, SCM-1β, Fractalkine, Neurotactin, ABCD-3, MIF, Macrophage migration inhibitory factor, glycosylation-inhibiting factor, 656 Hex2Sia1, 657 Hex2Fuc2, 730 Hex3HexNAc1, 876 Hex3HexNAc1Fuc1, 1022 Hex3HexNAc1Fuc2, 1095 Hex4HexNAc2, 1241 Hex4HexNAc2Fuc1, 1387 Hex4HexNAc2Fuc2, 1533 Hex4HexNAc2Fuc3, E-selectin, L-selectin, P-selectin, VCAM1, ICAM-1, Mucosal vascular cell-adhesion molecule 1 (MADCAM1), neutrophil β2-integrins (CD11a/CD18 (LFA-1) and CD11b/CD18), and combinations thereof.
2. The wound packing material of claim 1 , wherein the wound packing material comprises a foam.
3. The wound packing material of claim 1 , wherein the wound packing material comprises a gauze.
4. A wound dressing for use in negative pressure wound therapy, the wound dressing comprising an occlusive backing layer fitted with a drainage port, and a wound packing material of claim 1 .
5. A kit comprising:
a wound packing material as set forth in claim 1 ;
a cover material for forming a seal over a wound space; and,
connection for a negative pressure source.
6. A kit of claim 5 , wherein the kit is provided in a water-proof pack and in a sterile form.
7. A kit of claim 5 , wherein a pack containing the kit components is provided in a form whereby radiation and/or ethylene oxide can be used for sterilization.
8. A kit of claim 5 , further comprising at least one of an adhesive to fix wound dressings, an air-tight seal of wound dressings, a pressure sensor, a connection element for a pressure sensor, a disinfectant, a skin care product, instructions for use, scissors, pads and pincers.
9. The wound packing material of claim 1 , wherein the chemoattractant agent is chemoattractant to a human cell infected with a virus.
10. The wound packing material of claim 1 , wherein the chemoattractant agent is chemoattractant to a bacteria.
11. The wound packing material of claim 1 , wherein the chemoattractant agent is chemoattractant to a at least one microorganism selected from the group consisting of: Acinetobacter spp, Burkholdaria cepacia, Campylobacter jejuni, Candida albicans (binding proteins), Candida glabrata (binding proteins), Entamoeba histolytica (protozoan), Plasmodium spp (protozoan), Enterobacteria, Enterococcus (VRE), Escherichia coli, Helicobacter pylori, Klebsiella pneumonia, Listeria monocytogenes , Mucormycosis, Mycobacterium tuberculosis, Pasteurella spp, Propionibacterium acnes, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella typhi , paratyphi, Serratia marcescens and other Serratia spp, Shigella spp ( dysenteriae, flexneri, boydii, sonnei ), Staphylococcus aureus (CA MRSA, MRSA MSSA) biofilms, Staphylococcus epidermidis, Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes , and Vibrio spp.
12. The wound packing material of claim 1 , wherein the wound packing material does not comprise an antibiotic.
13. The wound packing material of claim 1 , wherein the wound packing material does not comprise an antimicrobial.
14. The wound packing material of claim 12 , wherein the pH of the wound packing material is between about pH 6 and about pH 8.
15. The wound packing material of claim 1 , wherein the chemoattractant agent comprises about 0.01% to about 30% by weight, relative to the total weight of the wound packing material.